Literature DB >> 26395386

Interaction between Streptococcus pneumoniae and Staphylococcus aureus in paediatric patients suffering from an underlying chronic disease.

Susanna Esposito1, Gian Luigi Marseglia2, Carla Colombo3, Lorenzo Iughetti4, Leonardo Terranova5, Valentina Ierardi5, Monia Gambino5, Nicola Principi5.   

Abstract

Little is known about the interaction between Streptococcus pneumoniae and Staphylococcus aureus in school-age children and adolescents suffering from an underlying chronic disease. To increase our knowledge in this regard, an oropharyngeal swab was obtained from school-age children and adolescents suffering from asthma (n = 423), cystic fibrosis (CF) (n = 212) and type 1 diabetes mellitus (DM1) (n = 296). S. pneumoniae detection and serotyping were performed using a real-time polymerase chain reaction, and S. aureus detection was performed using the RIDAGENE MRSA system. Among asthmatic, CF and DM1 patients, both pathogens were identified in 65/423 (15.4%), 21/212 (9.9%) and 62/296 (20.9%) children, respectively; S. pneumoniae alone was identified in 127/434 (30.0%), 21/212 (9.9%) and 86/296 (29.1%), respectively; S. aureus alone was identified in 58/434 (13.7%), 78/212 (36.8%) and 49/296 (16.6%), respectively. S. pneumoniae colonisation rates were higher in younger children and declined with age, whereas the frequency of S. aureus colonisation was quite similar in the different age groups. Among asthmatic and CF patients aged 6-9 years, S. aureus carriage was significantly higher in children who were positive for S. pneumoniae (P <0.05). No significant association emerged between S. aureus carriage and carriage of S. pneumoniae serotypes included in the pneumococcal conjugate vaccines (PCVs). This study shows for the first time that school-age children and adolescents with asthma, CF and DM1 are frequently colonised by S. pneumoniae and S. aureus and that no negative relationship seems to exist between these pathogens. Moreover, the supposed protection offered by PCV administration against S. aureus colonisation was not demonstrated.
© The Author(s) 2015.

Entities:  

Keywords:  Staphylococcus aureus; Streptococcus pneumoniae; pneumococcal colonisation; pneumococcal conjugate vaccine; staphylococcal colonisation

Mesh:

Substances:

Year:  2015        PMID: 26395386     DOI: 10.1177/0394632015601486

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  1 in total

1.  Prevalence and risk factors for Staphylococcus aureus nasopharyngeal carriage during a PCV trial.

Authors:  Abdoulie Bojang; Lindsay Kendall; Effua Usuf; Uzochukwu Egere; Sarah Mulwa; Martin Antonio; Brian Greenwood; Philip C Hill; Anna Roca
Journal:  BMC Infect Dis       Date:  2017-08-25       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.